European Archives - Page 37 of 1421 - European Medical Journal

haemodialysis

Cognitive Impairment and Physical Decline in Patients on Haemodialysis

Study finds high rates of cognitive impairment in haemodialysis patients, with poorer physical function seen in those with established cognitive decline.

GLP-1

Weight Loss Surgery Healthier for the Heart than GLP-1s

Metabolic and bariatric surgery offers greater cardiovascular protection than GLP-1 receptor agonists, a 2026 systematic review and meta-analysis has found.

early gastric cancer

AI Matches Experts in Diagnosing Early Gastric Cancer

Deep learning models have matched the diagnostic accuracy of expert endoscopists in detecting early gastric cancer.

coronary plaque

Leuprolide Tied to More Coronary Plaque in Prostate Cancer Progression

Randomised data show leuprolide is linked to greater 12-month coronary plaque progression than relugolix in men receiving ADT for prostate cancer.

ublituximab

Five Year Outcomes of Ublituximab in Multiple Sclerosis

Long-term ublituximab treatment reduces relapse rates and disability progression, reinforcing early intervention strategies in multiple sclerosis care.

B12

Scientists Find Lab Test Can Explain High Vitamin B12

Macro B12 may explain persistently raised vitamin B12 levels and help avoid unnecessary bone marrow biopsy in patients with low suspicion of malignancy.

Tanja Spanic

Fast Five: Tanja Spanic on Patient Advocacy Updates

In this episode, Tanja Spanic shares her perspective on the updated European Code Against Cancer…

Handshake

Gilead to acquire CAR-T biotech Arcellx for $7.8bn

The deal is a unified effort to advance a CAR T-cell therapy currently under regulatory review for multiple myeloma.

Two-Thirds of Women Stop Taking Antidepressants During Pregnancy

Nearly two-thirds of women stop taking prescribed antidepressants during pregnancy, a 2026 cross-sectional analysis has found.

DMT Rapidly Reduces Major Depression Symptoms

DMT therapy significantly reduced major depressive disorder symptoms in a phase IIa trial. Learn more about this rapid-acting psychedelic approach.